Key result
All aspirin formulations provided comparable overall plasma exposure, while effervescent tablets, fast-release tablets, and granules in suspension achieved higher Cmax and shorter Tmax.
Why the study?
How do different formulations of 500 mg aspirin affect the pharmacokinetic parameters of acetylsalicylic acid and salicylic acid?
How do different formulations of 500 mg aspirin affect the pharmacokinetic parameters of acetylsalicylic acid and salicylic acid?
Different formulations of 500 mg aspirin provide comparable overall exposure but differ significantly in absorption rate, with effervescent and fast-release formulations achieving faster and higher peak concentrations.
Answers are grounded in this paper and cite their sources.
Formulation differences may affect aspirin absorption speed in acute use; leaves open whether PK variations alter clinical efficacy or safety.
Aspirin has been used therapeutically for over 100 years. As the originator and an important marketer of aspirin-containing products, Bayer's clinical trial database contains numerous reports of the pharmacokinetics of various aspirin formulations. These include evaluations of plain tablets, effervescent tablets, granules, chewable tablets, and fast-release tablets. This publication seeks to expand upon the available pharmacokinetic information concerning aspirin formulations. In the pre-systemic circulation, acetylsalicylic acid (ASA) is rapidly converted into its main active metabolite, salicylic acid (SA). Therefore, both substances are measured in plasma and reported in the results. The 500 mg strength of each formulation was chosen for analysis as this is the most commonly used for analgesia. A total of 22 studies were included in the analysis. All formulations of 500 mg aspirin result in comparable plasma exposure to ASA and SA as evidenced by AUC. Tablets and dry granules provide a consistently lower Cmax compared to effervescent, granules in suspension and fast release tablets. Effervescent tablets, fast release tablets, and granules in suspension provide a consistently lower median Tmax compared to dry granules and tablets for both ASA and SA. This report reinforces the importance of formulation differences and their impact on pharmacokinetic parameters.
No takes yet. Share an insight, caveat, or question.
Kanani et al. (2015) conducted a review in Healthy volunteers. Aspirin formulations (effervescent, granules, chewable, fast-release) vs. Aspirin plain tablets was evaluated on Pharmacokinetic parameters including AUC, Cmax, and Tmax for acetylsalicylic acid and salicylic acid. All aspirin formulations provided comparable overall plasma exposure, while effervescent tablets, fast-release tablets, and granules in suspension achieved higher Cmax and shorter Tmax.
Synapse has enriched 10 related papers. Consider them for comparative context: